Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7300844 | 0.95 | AGTR1 (0.51) | AGTR1AGTR2 | |
| SCHEMBL7311121 | 0.94 | AGTR1 (0.51) | AGTR1AGTR2 | |
| SCHEMBL8860944 | 0.93 | AGTR1 (0.47) | AGTR1AGTR2 | |
| SCHEMBL9558700 | 0.92 | AGTR1 (0.52) | AGTR1AGTR2 | |
| SCHEMBL7889769 | 0.92 | AGTR1 (0.46) | AGTR1AGTR2 | |
| SCHEMBL9558459 | 0.91 | AGTR1 (0.57) | AGTR1AGTR2 | |
| SCHEMBL7305019 | 0.89 | AGTR1 (0.49) | AGTR1AGTR2 | |
| SCHEMBL7886537 | 0.89 | AGTR1 (0.45) | AGTR1AGTR2 | |
| SCHEMBL7883302 | 0.89 | AGTR1 (0.44) | AGTR1AGTR2 | |
| SCHEMBL7889507 | 0.89 | AGTR1 (0.43) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2174666-B1 | MEDICINAL AGENT FOR TREATMENT OF AMYLOID BETA-INDUCED CEREBRAL CIRCULATION OR CEREBRAL BLOOD FLOW DISORDERS | DAIICHI SANKYO CO LTD (JP) | 2013-12-18 | — | — | EP | claimed |
| US-20120302614-A1 | METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER | OSAKA UNIVERSITY (JP) | 2012-11-29 | — | — | US | claimed |
| US-20100130567-A1 | MEDICAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER 'S DISEASE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | claimed |
| EP-2174666-A1 | MEDICINAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE | Daiichi Sankyo Company, Limited (JP) | 2010-04-14 | — | — | EP | claimed |
| EP-1884240-B1 | PHARMACEUTICAL FOR PREVENTION OR TREATMENT OF BONE METABOLIC DISEASE | DAIICHI SANKYO CO LTD (JP) | 2009-11-11 | — | — | EP | claimed |
| US-20090082411-A1 | Pharmaceutical for prevention or treatment of bone metabolic disease | DAIICHI SANKYO COMPANY, LIMITED (75% INTEREST) (JP) | 2009-03-26 | — | — | US | claimed |
| EP-1884240-A1 | PHARMACEUTICAL FOR PREVENTION OR TREATMENT OF BONE METABOLIC DISEASE | Daiichi Sankyo Company, Limited (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20050119299-A1 | Ophthalmic solutions containing tetrazole derivatives | SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | claimed |
| EP-1488789-A1 | EYE DROPS CONTAINING TETRAZOLE DERIVATIVE | Sankyo Company, Limited (JP) | 2004-12-22 | — | — | EP | claimed |
| US-6777436-B2 | SYNERGISTIC MIXTURE OF ANGIOTENSIN INHIBITORS, BORIC ACID, ETHYLENEDIAMINETETRAACETIC ACID AND ACTIVE DRUG | SANKYO COMPANY, LIMITED (JP) | 2004-08-17 | — | — | US | claimed |
| US-20020147211-A1 | Intraocular tension lowering compositions for topical administration | SANKYO COMPANY, LIMITED (JP) | 2002-10-10 | — | — | US | claimed |
| EP-1186302-A1 | OCULAR TENSION LOWERING COMPOSITION FOR TOPICAL ADMINSTRATION | Sankyo Company, Limited (JP) | 2002-03-13 | — | — | EP | claimed |
| EP-0503785-B1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 2001-04-25 | — | — | EP | claimed |
| US-5616599-A | HYPOTENSIVE AGENTS FOR CARDIOVASCULAR DISORDER | SANKYO COMPANY, LIMITED (JP) | 1997-04-01 | — | — | US | claimed |
| EP-0503785-A1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1992-09-16 | — | — | EP | claimed |
| EP-2174666-B1 | MEDICINAL AGENT FOR TREATMENT OF AMYLOID BETA-INDUCED CEREBRAL CIRCULATION OR CEREBRAL BLOOD FLOW DISORDERS | DAIICHI SANKYO CO LTD (JP) | 2013-12-18 | — | — | EP | disclosed |
| US-20120302614-A1 | METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER | OSAKA UNIVERSITY (JP) | 2012-11-29 | — | — | US | disclosed |
| US-5646171-A | HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-07-08 | — | — | US | disclosed |
| US-5616599-A | HYPOTENSIVE AGENTS FOR CARDIOVASCULAR DISORDER | SANKYO COMPANY, LIMITED (JP) | 1997-04-01 | — | — | US | disclosed |
| EP-0503785-A1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130567-A1 | MEDICAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER 'S DISEASE | AGTR1, AGTR2, ACE | AGTR1 1/4885AGTR2 2/4885 |
| US-20050119299-A1 | Ophthalmic solutions containing tetrazole derivatives | TCOF1, F12, TTI1 | AGTR1 563/4885AGTR2 1110/4885 |
| US-20120302614-A1 | METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER | AGTR2, AGTR1, BDKRB2 | AGTR1 2/4885AGTR2 1/4885 |
| US-20090082411-A1 | Pharmaceutical for prevention or treatment of bone metabolic disease | AGTR1, AGTR2, MC2R | AGTR1 1/4885AGTR2 2/4885 |
| US-20020147211-A1 | Intraocular tension lowering compositions for topical administration | AGT, ECE1, AGTR1 | AGTR1 3/4885AGTR2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.